SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:kth-346504"
 

Sökning: id:"swepub:oai:DiVA.org:kth-346504" > Half-life extension...

  • Zhang, JieKTH,Proteinvetenskap,KTH Royal Inst Technol, Dept Prot Sci, Roslagstullsbacken 21, S-11417 Stockholm, Sweden. (författare)

Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • Elsevier BV,2024
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:kth-346504
  • https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-346504URI
  • https://doi.org/10.1016/j.jconrel.2024.04.051DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-532220URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • QC 20240520
  • A critical parameter during the development of protein therapeutics is to endow them with suitable pharmacokinetic and pharmacodynamic properties. Small protein drugs are quickly eliminated by kidney filtration, and in vivo half-life extension is therefore often desired. Here, different half-life extension technologies were studied where PAS polypeptides (PAS300, PAS600), XTEN polypeptides (XTEN288, XTEN576), and an albumin binding domain (ABD) were compared for half-life extension of an anti-human epidermal growth factor receptor 2 (HER2) affibody-drug conjugate. The results showed that extension with the PAS or XTEN polypeptides or the addition of the ABD lowered the affinity for HER2 to some extent but did not negatively affect the cytotoxic potential. The half-lives in mice ranged from 7.3 h for the construct including PAS300 to 11.6 h for the construct including PAS600. The highest absolute tumor uptake was found for the construct including the ABD, which was 60 to 160% higher than the PASylated or XTENylated constructs, even though it did not have the longest half-life (9.0 h). A comparison of the tumor-to-normal-organ ratios showed the best overall performance of the ABD-fused construct. In conclusion, PASylation, XTENylation, and the addition of an ABD are viable strategies for half-life extension of affibody-drug conjugates, with the best performance observed for the construct including the ABD.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bodenko, VitalinaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia, Tomsk Polytechnic University; Scientific and Educational Laboratory of Chemical and Pharmaceutical Research, Siberian State Medical University, Ministry of Health of the Russian Federation, 634050 Tomsk, Russia,Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634050, Russia.;Siberian State Med Univ, Sci & Educ Lab Chem & Pharmaceut Res, Minist Hlth Russian Federat, Tomsk 634050, Russia. (författare)
  • Larkina, MariaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia, Tomsk Polytechnic University; Siberian State Medical University, Ministry of Health of the Russian Federation, 634050 Tomsk, Russia; National Research Tomsk Polytechnic University, 634050 Tomsk, Russia,Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634050, Russia.;Siberian State Med Univ, Minist Hlth Russian Federat, Tomsk 634050, Russia. (författare)
  • Bezverkhniaia, EkaterinaUppsala universitet,Theranostics,Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634050, Russia.(Swepub:uu)ekabe208 (författare)
  • Xu, TianqiUppsala universitet,Institutionen för immunologi, genetik och patologi(Swepub:uu)tiaxu272 (författare)
  • Liao, YunqiUppsala universitet,Institutionen för immunologi, genetik och patologi (författare)
  • Abouzayed, AymanUppsala universitet,Theranostics,Translationell avbildning med PET(Swepub:uu)aymab857 (författare)
  • Plotnikov, EvgeniiResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia, Tomsk Polytechnic University,Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634050, Russia. (författare)
  • Tretyakova, MariaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia, Tomsk Polytechnic University,Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634050, Russia. (författare)
  • Yuldasheva, FeruzaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia, Tomsk Polytechnic University,Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634050, Russia. (författare)
  • Belousov, Mikhail V.Uppsala universitet,Institutionen för läkemedelskemi,Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk 634050, Russia. (författare)
  • Orlova, Anna,1960-Uppsala universitet,Theranostics,Cancerprecisionsmedicin(Swepub:uu)annaorlo (författare)
  • Tolmachev, VladimirUppsala universitet,Cancerprecisionsmedicin(Swepub:uu)vladtolm (författare)
  • Gräslund, Torbjörn,1970-KTH,Proteinvetenskap,KTH Royal Inst Technol, Dept Prot Sci, Roslagstullsbacken 21, S-11417 Stockholm, Sweden.(Swepub:kth)u1dl39rj (författare)
  • Vorobyeva, AnzhelikaUppsala universitet,Cancerprecisionsmedicin(Swepub:uu)anzvo555 (författare)
  • KTHProteinvetenskap (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Controlled Release: Elsevier BV370, s. 468-4780168-36591873-4995

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy